News Ionis hit by safety concerns, rivals Alnylam benefit Biotech insists drug for rare inherited disorder is still approvable.
Cancer AZ confirms move to acquire cancer specialist Acerta Acerta brings with it a promising lead candidate
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
